FDA Clears Sickle Cell Drug, Casgevy, to Treat Transfusion-Dependent Beta-Thalassemia

WEDNESDAY, Jan. 17, 2024 -- Casgevy, a groundbreaking treatment that was approved to treat sickle cell disease in December, was given the U.S. Food and Drug Administration's blessing on Tuesday to treat another inherited blood disorder.

Casgevy is...